The 10th Geriatric Medicine Society Meeting - Generally Assembly 2016 took place in Frankfurt (Germany) on May 2, 2016. The meeting addressed specifically the perception and behaviors of older adults regarding their disease and therapy experience. Members presented very interesting results from studies performed in older patients to capture drug product experience and perception. Solutions and opportunities to address the challenges of including patient centricity into industrial processes through interdisciplinary collaboration were suggested as a way forward. The minutes of the meeting can be send upon request to: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.


The 2016 GSA Annual Scientific Meeting will be held in New Orleans, LA (USA) from November 16 – 20, 2016 under the major theme of “New lens on aging – changing attitudes, providing possibilities”. About 4000 experts from around the world will gather to discuss the latest developments in aging research covering all areas from health care provision through to new opportunities of healthy aging in inclusive communities (https://www.geron.org/meetings-events/2016-gsa-annual-scientific-meeting)


“Discovering new ways in the world of geriatrics” is the headline for the 12th EUGMS Congress 2016, which will take place in Lisbon (Portugal) from October 5 -7, 2016. The conference will provide insight into the latest developments in geriatrics and gerontology involving the various stakeholders in the fields (http://www.eugms.org/2016.html)


The 10th Worldmeeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP) will be held in Glasgow (UK) from April 4 – 7, 2016. This meeting will focus on the address some of the key advances in developing and manufacturing pharmaceutical drug products to enhance the therapeutic outcome. Continuous manufacturing, printing medicines and ophthalmic drug delivery are some of the key areas that will be brought forward (http://www.worldmeeting.org/home/). For further information, please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it. .


The EUFEPS Annual Meeting 2016 is dedicated to the “Clinical Outcome and Regulatory Approaches for Advanced Drug Delivery Products” bringing together a faculty of global experts in the relevant fields. The Annual Meeting 2016, being held in Istanbul (Turkey) from June 13 – 15, 2016 will also celebrate the 25th Anniversary of EUFEPS (http://www.eufeps.org/node/99).


The European Commission along with the Dutch Ministry of Health and the HIMSS is organizing a Conference on the use of Information and Communication Technology (ICT) in the healthcare provision. The eHealth week will take place in Amsterdam from June 6 – 10, 2016 and focus on empowering people, trust & standards and innovation & transition. Further information can be found on the internet (http://www.ehealthweek.org/ehome/index.php?eventid=128630&)


The European Commission announced that it will start the Innovative Medicine Initiative 2 (IMI 2) on July 9, 2014. The draft proposals of call 1-Topics (1) Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM) and (2) Discovery and validation of novel endpoints in retinal diseases can be received from the IMI web-site. Additional information on the IMI 2 are available on the web as well http://www.imi.europa.eu/content/imi-2


The American Association of Pharmaceutical Scientists (AAPS) is starting a new Focus Group called “Patient centric drug development, drug product design, and manufacturing” which will address the needs of the targeted patients within a development program taking into account their specific characteristics in terms of age, physiology, morbidity/co-morbidity, functional impairments, co-medications, etc. The geriatric patient population is expected to be one of the most important patient populations of future drug development. The new Focus Group is aiming for interdisciplinary discussions involving formulation, clinical, regulatory and manufacturing experts and directed towards scientifically proven solutions. For further information please consult https://www.aaps.org/default.aspx


The Geriatric Medicine Society has published a critical commentary titled: “Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models” in the Z. Gerontol Geriat (DOI: 0.1007/s00391-014-0647-4). The commentary summarizes the outcomes of several multidisciplinary discussions and is intended to stimulate further discussions.


In February GBI Research published a report called “Geriatric Medicine Development - Carving Out New Opportunities to Treat Age-Related Diseases” focusing on the challenges and opportunities for drug product development in the aging society. For more information on the report please consult: http://www.gbiresearch.com/Report.aspx?ID=CBR-Pharma-Geriatric-Medicine-Development-Carving-Out-New-Opportunities-to-Treat-AgeRelated-Diseases


European Medicines Agency (EMA) has released two Report analyses as part of their Geriatric Medicines Strategy on October 14, 2013. The “Report analysis on Product information” reviews the appropriateness of the product information of the new product submissions in the first year of the geriatric medicine strategy implementation. They found a high acceptance rate and of appropriate product information for healthcare professionals. The “Report analyses of scientific guidelines” is looking into the number of scientific guidelines that have been reviewed or commented between 2011 and 2013 and include the relevant comments to reflect the geriatric patient population. From 28 relevant guidelines, 18 have been adopted of which 10 have taken the comments about the older adults patient population fully or partially into consideration.


European Medicines Agency (EMA) released its “Proposal for the development of a points to consider for baseline characteristics of frailty status” on May 30, 2013. The development of the document “Points to consider” should cover three main areas, physical frailty, comorbidity status and mental frailty.


On March 20, 2013 the EMA published their “Concept paper on the needs for a reflection paper on quality aspects of medicines for older adults” which aims to provide considerations for future pharmaceutical development of medicines to reflect the increasing age of the patients. The drafting period of the reflection paper is foreseen for Q3 2013 to Q3 2014 with consultation and finalization by end of 2015. The concept paper can be downloaded from the EMA web-site.


The European Innovative Partnership (EIP) on Active and Healthy Aging has published the Action Plans on November 6, 2012. The actions cover the areas of adherence to prescription, falls prevention, prevention of functional decline and frailty, integrated care, independent living and age friendly environment. Details can be found on the EIP website.


A one day conference on “Medicines for older adults: Learning from practice to develop patient centric drug products” was held in collaboration with the APS and the UCL in Stevenage (UK) on March 13, 2013. Clinicians, hospital pharmacists, regulators and pharmaceutical scientists discussed the challenge in development and provision of pharmaceutical products to older adults. http://www.apsgb.org/Events/20130313/Default.asp


AAPS Pre-Conference Workshop: “Patient Centric Drug Delivery, Product Design and Development: Meeting the Requirements in Future Healthcare”
The workshop which took place on October 13-14, 2012 in Chicago brought together global experts from healthcare providers, regulatory authorities, clinicians and industrial scientists to discuss the future role of patient centricity in the provision of high quality healthcare products. The interdisciplinary discussions provided several angles to increase the appropriateness of healthcare products for patients and consequently their adherence.


The report from the European Medicines Agency (EMA) Workshop: Ensuring safe and effective medicines for an ageing population has been published.
On March 22 – 23, 2012 the “EMA workshop on ensuring safe and effective medicines for an aging population” took place in London. The objective of this workshop was to address the challenges caused by an aging population on the future development, regulation, prescribing and marketing of pharmaceutical products. The Geriatric Medicine Society has contributed the results of our “Working Group on Adherence & Adherence Measurement” to the workshop.


European Innovation Partnership on Active and Healthy Ageing (EIP) was held in Brussels on April 3, 2012
On April 3rd, 2012 the European Commission (DG Health and Consumers and DG Information Society and Media) held its next Conference on the "European Innovation Partnership on Active and Healthy Ageing. From Plan to Action" in Brussels.
The Conference was dedicated to the presentation of the Strategic Implementation Plan of this pilot European Innovation Partnership (http://bit.ly/ufJdZ5) and provided information on how to participate and contribute with commitments to the European Innovation Partnership on Active and Healthy Ageing.


European Medicines Agency (EMA) Workshop: Ensuring safe and effective medicines for an ageing population took place on March 22 – 23, 2012 in London.
On March 22 – 23, 2012 the “EMA workshop on ensuring safe and effective medicines for an aging population” took place in London. The objective of this workshop was to address this challenge, action in the geriatric field is a priority in the EMA Road Map 2015 and CHMP work-program 2011-13 as older adults are the fastest-growing segment of the total population and especially the oldest old—people 80 and over. The workshop was part of the EMA geriatric medicines strategy, involving stakeholders to discuss the initial steps and explore future directions.
The Geriatric Medicine Society has contributed the results of our “Working Group on Adherence & Adherence Measurement” to the workshop.
All presentations are now published on the EMA website.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2011/10/event_detail_000542.jsp&mid=WC0b01ac058004d5c3

Please click on all documents for downloads of the presentations. For all other enquiries reach out to: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.


8th Worldmeeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology held in Istanbul March 19 – 22, 2012
More than 1400 scientists attended the 8th Worldmeeting organized by 3 major European Pharmaceutical Organization the APGI (French “Association de Pharmacie Galénique Industrielle”), APV (German “International Association for Pharmaceutical Technology”) and A.D.R.I.T.E.L.F. (Italian “Associazione Docenti Ricercatori Italiani di Tecnologie e Legislazione Farmaceutiche”). The Geriatric Medicine Society presented the results of its “Drug Formulation and Dosage Form Working Group”.


Special Eurobarometer 378 on Active Ageing was published in January 2012
The Directorate-General for Employment, Social Affairs and Inclusion and co-ordinated by Directorate-General for Communication has requested a survey to understand European citizens’ views and attitudes towards older people, the contribution of older people in the workplace and society, and how best to promote an active role of older people in society. The survey was conducted by TNS Opinion & Social in 27 member states from September to November 2011 and included 31.280 responses from people of 15 years and above. Even so the outcomes do not represent the official opinion of the European Commission the report provides a good insight into the perception of older people and ageing and the integration of older adults into our society throughout Europe. The report can be downloaded following the link
http://ec.europa.eu/public_opinion/archives/ebs/ebs_378_en.pdf


BIT 1st Annual Symposium of Drug Delivery Systems, Shenzhen (China)
The Geriatric Medicine Society chaired a session and presented on Strategic planning for patient centric drug delivery on November 3, 2011. While China accounts for one of the strongest growth areas for pharmaceutical products with the same demographic changes as in the mature markets, the session brought the topic of geriatric medicine to the attention of scientists in the emerging markets.


AAPS Annual Meeting, Washington (USA)
The Geriatric Medicine Society organized the session “Towards individualized medical care: Preparing for patient centered drug therapy.” at the AAPS in Washington on October 24, 2011. Presentations covered various aspects of drug product design from a patient as well as from an industrial perspective. The presentations were provided by Sven Stegemann (Geriatric Medicine Society), Judith Beizer (St John’s University), Nahed Mohsen (Exponent) and Johannes Khinast (TU Graz) will be available for download from the AAPS website (www.aaps.org)


General Assembly of the Geriatric Medicine Society 2011
The General Assembly 2011 took place on October 14, 2011 in Frankfurt. To receive a copy of the minutes please follow the link.


Futurage Road Map
On October 18, 2011 the European Commission hosted a conference to launch the “Futurage: A Road Map for European aging research” in Brussels. The Road Map for ageing research is based on extensive consultation in this field over a period of 2 years, involving all of the major stakeholder groups and end users of ageing research. The document can be downloaded at (http://www.futurage.group.shef.ac.uk/road-map)


Berlin Aging Study II (BASE II): Health and Cognitive Functioning across the Lifespan
The Berlin Aging Study is a multidisciplinary and longitudinal study evaluating the mental and physical health, the psychological functioning, and the social and economic situation of people between 70 to over 100 years. Funded by the Federal Ministry for Family Affairs, Senior Citizens, Women and Youth the Berlin Aging Study II has been launched.
The Berlin Aging Study II (BASE II) is an extension and expansion of the Berlin Aging Study (BASE) that was enrolled between 1990 -1993 and included 516 participants. This new study with more than 2,200 participants of different ages aims to complement the analysis of cognitive development across the lifespan by including socio-economic and biological factors such as living conditions, health, and genetic preconditions. (http://www.base-berlin.mpg.de/BASE_II.html)


On July 19, 2011 the European Commission has published its FP7 Work Programme 2012, Cooperation – Theme 1 – Health. The ‘Work Programme 2012’ on health will be part of the realization of the European Innovation Partnership (EIP) on "active and healthy ageing" that was initiated in 2010. The Health ‘Work Programme 2012’ has an indicative budget of EUR 684 million and aims to improve a healthy, active and independent life until old age, to ensure sustainable and efficient social and healthcare systems; and to position Europe in a global market of innovative products and services attributed to healthy and active ageing . Click here to download the Work Programme 2012 pdf.


On June 7, 2011 the European Medicines Agency (EMA) has published information about their recently formed CHMP Geriatric Expert Group (GEG), which has been established to help implementing the EMA Geriatric Medicines Strategy published earlier this year. The GEG will give their input on the specific aspects on geriatric medicines development, product evaluation and pharmacovigilance. The CHMP GEG will initially start with 9 members and one representative from the EMA secretariat and will focus on clinical and methodological issues. Due to the multidisciplinary aspects of geriatric medicines, experts from other than the directly involved disciplines (e.g. physicians, clinical pharmacologists) will be included as needed. The detailed information can be down-loaded from the EMA web site.


The 1st Multidisciplinary Expert Meeting was held on March 16, 2011 in Munich (Airport) in Germany.
The multidisciplinary expert meeting brought together experts from the different disciplines and societies involved in geriatric drug therapy.  The Experts concluded that the higher life expectancy and change in demographics need to be reflected in the development, regulation, prescription and use of drugs for older adults. The increasing morbidity, polypharmacy and heterogeneity in this patient population require individualization of the therapy and inclusion of the specific patient needs into the therapy. Due to the complexity of the overall drug therapy process advances will most likely occur in concerted strategy across all stakeholders including the patient involved in the drug therapy of older adults. The expected outcomes are an improved health and independence of older adults along with enhanced efficiency in healthcare provision. This will require investments into disciplinary, cross-disciplinary and multi-disciplinary research.
The minutes of the Expert Meeting are available here.


The European Medicines Agency published on its Geriatric Medicines Strategy (EMA/CHMP/137793/2011) and road map to 2015 to address the demographic changes to the needs of the increasing elderly patient population in the development and evaluation of new medicines. The objective of the Agency is to ensure that the medicines are adequate for older people and are of high quality and studied in the older population. This includes the launch of the products but also the entire lifecycle of the product to continuously increase the availability of information on the use of medicines in older adults.
www.ema.europa.eu/docs/en_GB/document_library/Other/2011/02/WC500102291.pdf


The FDA published a Draft Guideline called “Guidance for Industry: Size of beads in drug products labeled for sprinkle”, a drug delivery technology used to apply oral medicinal products to patient populations with swallowing issues like pediatric and geriatric patients.
The guideline can be down-loaded from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM240243.pdf


The European Commission published the Report from the stakeholder Consultation Conference on the European Innovation Partnership on Active and Healthy Aging, held in Brussels on November 26, 2010.
The report and the presentations can be accessed on:
http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing&pg=home.


The European Commission DG SANCO published a Reflection Paper derived from 3 Ageing workshops held on October 11, 12 and 18, 2010
The documents can be downloaded from the following web-site:
http://ec.europa.eu/health/ageing/policy/index_en.htm


The European Community launches the “European Innovation Partnership on active and healthy ageing”
Submissions can be made until January 28, 2011 and can be accessed through the following web-site:
http://ec.europa.eu/information_society/activities/einclusioii/deployment/ahaip/consultation/index_en.htm

 

Webdesign by Tostaky